Tyra Biosciences announced initial results from a Phase 2 trial of its cancer drug dabogratinib, revealing significant Grade 3 adverse events in patients. Following this, the company's stock fell nearly 18%. Pomerantz LLP is investigating whether Tyra and its executives engaged in securities fraud or unlawful practices related to the trial data disclosure. Investors affected by the stock drop are advised to contact the law firm for potential class action participation.
Tyra Biosciences is the subject of an investor investigation following adverse trial results. For readers following the health sector, here is Pluang's market snapshot as of Sep 17, 2026 19:42 WIB: 74 of 91 health-sector stocks rose today. Notable movers include Twist Bioscience Corp at USD 148.47 with a 3.77% increase, AbCellera Biologics Inc at USD 12.07 up 3.43%, and Ascendis Pharma A/S at USD 239.50 down 3.31%.
AX1 has launched Console 2.0, a platform on the Base blockchain that lets AI agents perform tasks and get paid in USDC using the x402 payment standard by Coinbase. This new version simplifies setup, allowing users to deploy AI agents quickly to work ...
The global generator cooling systems market is projected to grow from $3.76 billion in 2026 to $5.03 billion by 2031 at a CAGR of 6.0%. Growth is fueled by rising demand for reliable backup and continuous power in expanding data centers, industrial f...
The global computed tomography (CT) market is undergoing significant innovation driven by photon-counting technology, AI integration, mobile imaging, and point-of-care applications. These advancements are enhancing image quality, workflow efficiency,...
Global zinc supply is expected to fall short by 88,000 tonnes in 2026 amid declining mine production, while tin demand is projected to outpace supply growth through 2035. This has renewed exploration in historic polymetallic mining districts in the U...
Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...
